ResearcherTUM KlinikumNo recent work listed
Katharina Lankes
Matched on OpenAlex author ID A5029131363. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2020: 1 paper · 2021: none · 2022: 2 papers
Papers 3
- HDAC2 Facilitates Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-20-3209↗
- Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. First author DOI 10.1172/jci.insight.151353↗
- Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. Co-author DOI 10.1002/1878-0261.12835↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zonera Hassan · 3 shared papers, 2020–2022 · strength 0.32
- Paper HDAC2 Facilitates Pancreatic Cancer Metastasis. DOI 10.1158/0008-5472.can-20-3209↗
- Paper Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. DOI 10.1172/jci.insight.151353↗
- Paper Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. DOI 10.1002/1878-0261.12835↗
- Maximilian Reichert · 3 shared papers, 2020–2022 · strength 0.32
- Paper HDAC2 Facilitates Pancreatic Cancer Metastasis. DOI 10.1158/0008-5472.can-20-3209↗
- Paper Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. DOI 10.1172/jci.insight.151353↗
- Paper Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. DOI 10.1002/1878-0261.12835↗
- Roland Rad · 3 shared papers, 2020–2022 · strength 0.32
- Paper HDAC2 Facilitates Pancreatic Cancer Metastasis. DOI 10.1158/0008-5472.can-20-3209↗
- Paper Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. DOI 10.1172/jci.insight.151353↗
- Paper Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. DOI 10.1002/1878-0261.12835↗
- Günter Schneider · 3 shared papers, 2020–2022 · strength 0.32
- Paper HDAC2 Facilitates Pancreatic Cancer Metastasis. DOI 10.1158/0008-5472.can-20-3209↗
- Paper Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. DOI 10.1172/jci.insight.151353↗
- Paper Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. DOI 10.1002/1878-0261.12835↗
- Matthias Wirth · 3 shared papers, 2020–2022 · strength 0.32
- Paper HDAC2 Facilitates Pancreatic Cancer Metastasis. DOI 10.1158/0008-5472.can-20-3209↗
- Paper Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. DOI 10.1172/jci.insight.151353↗
- Paper Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. DOI 10.1002/1878-0261.12835↗
- Dieter Saur · 3 shared papers, 2020–2022 · strength 0.32
- Paper HDAC2 Facilitates Pancreatic Cancer Metastasis. DOI 10.1158/0008-5472.can-20-3209↗
- Paper Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. DOI 10.1172/jci.insight.151353↗
- Paper Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. DOI 10.1002/1878-0261.12835↗
- Lukas Krauß · 2 shared papers, 2022 · strength 0.23
- Carolin Schneider · 2 shared papers, 2022 · strength 0.23
- Roland Michael Schmid · 2 shared papers, 2022 · strength 0.23
- Oliver Holger Krämer · 2 shared papers, 2020–2022 · strength 0.21
- Christian Schneeweis · 2 shared papers, 2020–2022 · strength 0.21
- Yonggan Xue · 1 shared paper, 2022 · strength 0.11
- Felix Orben · 1 shared paper, 2022 · strength 0.11
- Bernhard Küster · 1 shared paper, 2022 · strength 0.11
- Christoph Schlag · 1 shared paper, 2022 · strength 0.11
- Janine Murr · 1 shared paper, 2022 · strength 0.11
- Georg Beyer · 1 shared paper, 2022 · strength 0.11
- Julia V. Mayerle · 1 shared paper, 2022 · strength 0.11
- Bo Kong · 1 shared paper, 2022 · strength 0.11
- Ujjwal Mukund Mahajan · 1 shared paper, 2022 · strength 0.11
- Josefina Doffo · 1 shared paper, 2020 · strength 0.10
- Ulrich Bernd Keller · 1 shared paper, 2020 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.